| Literature DB >> 30468147 |
Miha Tibaut1, Martin Caprnda2, Peter Kubatka3, Andreja Sinkovič4, Vanda Valentova5, Slavomira Filipova6, Katarina Gazdikova7, Ludovit Gaspar8, Ioana Mozos9, Emmanuel E Egom10, Luis Rodrigo11, Peter Kruzliak12, Daniel Petrovic13.
Abstract
Atherosclerosis is a major contributor to morbidity and mortality worldwide. With therapeutic consequences in mind, several risk scores are being used to differentiate individuals with low, intermediate or high cardiovascular (CV) event risk. The most appropriate management of intermediate risk individuals is still not known, therefore, novel biomarkers are being sought to help re-stratify them as low or high risk. This narrative review is presented in two parts. Here, in Part 1, we summarise current knowledge on serum (serological) biomarkers of atherosclerosis. Among novel biomarkers, high sensitivity C-reactive protein (hsCRP) has emerged as the most promising in chronic situations, others need further clinical studies. However, it seems that a combination of serum biomarkers offers more to risk stratification than either biomarker alone. In Part 2, we address genetic and imaging markers of atherosclerosis, as well as other developments relevant to risk prediction.Entities:
Keywords: Atherosclerosis; Biomarkers; High sensitivity C-reactive protein
Mesh:
Substances:
Year: 2018 PMID: 30468147 DOI: 10.1016/j.hlc.2018.06.1057
Source DB: PubMed Journal: Heart Lung Circ ISSN: 1443-9506 Impact factor: 2.975